Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Advocates Press For US FDA Rare Disease Center Of Excellence

Executive Summary

Attorneys' proposal aims to better connect dispersed rare disease expertise within FDA's drug, biologic, and device centers through more leadership, new advisory committee.

Related Content

US FDA May Create Rare Disease Expert Pool For Advisory Committee Reviews
US FDA Considering Contracting IT Services To Keep Systems Up To Date, Break Down Siloes
US FDA's Streamlined Hiring Pilot Restarts After Delay
US FDA's Rare Diseases Program Not Expected To Change With Drug Office Reorg
US FDA's Cancer Review Staff Should All Move To Oncology Center of Excellence, Advocates Say
US FDA May Create Immunology, Neuroscience Centers Of Excellence
US FDA May Change Advisory Committee Planning, Member Screening
Rare Disease Integration Into FDA Reviews Will Grow Under PDUFA VI
Orphan Drug Reviews: Industry Wants FDA To Move Out Of Its Comfort Zone





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts